Fixed drug eruption (FDE) is manifested as localized, circumscribed, round or oval plaques that characteristically recur in the same site with each use of the offending drug. The drugs most commonly implicated are phenolphthalein, barbiturates, antibiotics, salicylates, contraceptives, and anticonvulsants.
Fixed drug eruption (FDE), first described by Brocq (l) , is a sharply demarcated, circumscribed, round or oval dermatitis that characteristically rectlrs in the same site each time a particular drug is administered (2). The diagnostic hallmark of FDE is its recurrence at previously affected sites (3). The lesions can appear on any part of the body and vary in severity from a small, localized lesion to generalized involvement. The list of oflending drugs is very long. FDEs are seen in 220/. of children with cutaneous drug reaction (4). Twenty percent of the patients had genital lesions.
We describe 15 boys with genital FDE. To the best of our knowledge, this is the largest pediatric series of genital FDE to date.
PATIENTS ANI) METHODS
Our file review for the years 1987-2000, of patients admitted to the Department of Pediatrics, Hasharon Hospital and Schneider Children's Medical Center of Israel, yielded 15 boys with a diagnosis of genital FDE. The clinical presentation usually consisted of swelling and et-ythema of the penis and/or scrotum associated with pruritus, restlessness, urinary retention, or painful micturation. The offending drugs were paracctatnol, co-trimoxazoic, hydroxyzinehydroch] oriole,nlethylpheniciate, mctronidazole, phenobarbital, and tetracycline.
[n each case the eruption appeared after a specific drug was ingested and completely resolved after the drug was discontinued, The diagnosis was supported by clinical history and in some cases by recurrence after rcchallengc and a positive migration inhibiting Factor (M IF) assay. No skin biopsies were done.
The MIF test detects the release of lymphokines from lymphocytes in an in vitro setting when placed in contact with a drug that presumably had sensitized them in vivo. Samples of peripheral blood lymphocytes from the patients and controls were prepared separately and mixed with guinea pig macrophages at a ratio of l:4 in capillary tubes. They were placed in incubation chambers and tested with optimal blood concentrations of the drugs and in the absence of drugs. After 24 hours of incubation in5°/0 C02 at 37°C, thearea ofmigrationof the macrophages in the samples was calculated as the migration index, which is the area of migration with added drug versus the area of migration without the drug. Table 1 shows the demographic and clinical characteristics of the patients. The average age at diagnosis was 3.2 +2.2 years (range 6 nlonths-8 years). Systemic manifestations like fever, Iymphadenopathy, and mucosal involvement evidenced as erosions were seen in 3 (20VO)patients. Thelagperiod between drug administration and the skin eruption was variable (mean 72 hours; range 1-168 hours). No apparent association was observed between the duration of the lag period and either patient age or responsible drug. Previous exposure to the specific drug was difficult to evaluate. The MI F test detected the drugs responsible for II of 12 allergic episodes (91.60/0). The fixed drug eruptions in these patients (80Yo) included pruritic papularerythematous patches on thegenita]ia; 200/0 became bullous, edematous, and/or eroded. The majority of these lesions occurred on the glans (470/0). Other sites involved were the shaft (20Yo) and the scrotum (33%) (Fig. l) .
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DISCUSS1ON
The cutaneous eruption in FDE is characterized by erythcmatous patches which are variable in size and progressively turn dusky, violaceous, or brown; some of the lesions are vesicular or bullous. Systemic nlanifestations are uncommon. The eruption usually develops 30 minutes to 8 hours after administration of the offending drug. Histopathologic examination of the lesions reveals a mononuclear cell infiltrate near the dermoepidermal junction. Basal cell degeneration can lead to the formation of bulhte. In the late stages, melanin-laden macrophages are present in the dermis. Treatment consists of removal of the o~ending drug. Thereafter the lesions become crusty and scaly and then fade over a period of 1-2 weeks. Hyperpigmented patches are the most common sequelae, lasting for months and beeoming more pronounced after every recrudescent. The incidence of FDE is not well established. It has been reported in all age groups, although it may be more common in adults because of their increased drug exposure over time. The lesions can occur on any part of the skin or mucous membranes; the most common sites are the trunk, extremities, and genitalia. Most of the published series of FDE involve adult populations. Genital FDE has been reported in some case reports of adult patients (5) and in small series of children (6-9). FDEs were seen in 22% of children with cutaneous drug reactions in one study (10), but we suspect the FDEs are still underdiagnosed by most primary care child health providers. FDEs can appear anywhere on the body. In one series, the lips were the most commonly affected site and 20.20/. of the patients had genital lesions (4). In all previous studies, the number of males was greater than females (3-5, 10, 11). Genital mucosa was predominately affected in males, whereas extramucosal lesions were predominantly observed in females (1O). A report from Italy suggested a strong (p <0.000 I) association of FDE with HLA-B22 and CWI antigen (12).
Many drugs can cause fixed eruptions, including phenolphthalein, barbiturates, antibiotics (penicillin, tetracycline, sulfonamides, crythromycin, metronidazole), quinine, contraceptives, salicylates, and phenytoin. The list of drugs that reportedly cause genital involvement is significantly shorter than that for other areas of the body, but it is steadily growing ( Table 2) . Thankappan and Zachariah (13) suggested that the clinical pattern and anatomic distribution of the lesions in FDE are influen~d by the drug in question. In their series (mostly adults), all instances of FDE caused by tetracycline involved only the male genitalia, whereas other drugs (co-trimoxazolej pyrazolones) affected the male genitalia in addition to other anatomic sites, particularly the lips and limbs. The predilection for the male genitalia in tetracycline-induced FDE has been confirmed by other authors (14). Nevertheless, a generally significant relationship between specific drugs and areas of anatomic involvement has not been established (15) and it is significantly weaker with regard to all drugs except tetracycline.
The pathogenesis of FDE is not clear. Localized delayed-type hypersensitivity, local enzyme deficiency, and reaginic hypersensitiviy have all been suggested as part of the pathophysiologic process. Eosinophilia, elevated serum levels of IgA and lgG, and IgG and C3 intercellular deposits in affected epidermis have all been demonstrated (3). Korkij andSoltani(16) proposed that in the circulation, the offending drug may act as a hapten and bind to protein components or receptor cells of the lower dermis. As in allergic contact dermatitis, this drugprotein complex is then detected, processed, and presented by the Langerhans cells to lymphocytes in the dcmlis or regional lymph nodes, resulting in lymphocyte stimulation. The reason for the preferential localization of the lesions to certain skin sites remains speculative (3).
The diagnostic hallmark of FDE is its recurrence at previously affected sites, and clinical history is therefore one of the most important diagnostic tools. Probably only a provocation test with the suspected drug would provide su~cient proof of its role in the eruption, but the justification for such testing is doubtful because of the potential risk involved. Patch tests and intmcutaneous tests are of unconfirmed assistance (l i, 17). M IF, a Iymphokine released from sensitized T lymphocytes by the appropriate antigen, is considered to correlate with cell-mediated immunity, and in vitro M 1F assay is a reliable lest for the identification of hypersensitivity r~~ctions to drugs (18). The positive MIF test in 91.6°/0of our patients supported the diagnosis.
The di~crential diagnosis of genital FDE may include Reiter syndrome with balanitis, herpes genitalis, lichen planus, and contact dermatitis. History, lesion nlorphology, response to drug manipulation, positive MIF test, and clinical follow-up all assist to rule out these conditions. Though a lag period of some hours is usual between the drug administration and the skin eruption, in some of our patients it was as long as 2-3 days. We hypothesize that in children who probably have less previous drug exposure than adults, a "sensitization period" is necessary before the clinical manifestation of this immunoloQc process. Therefore the patient's age, immune status, and previous drug exposure are all crucial considerations in the diagnosis.
In conclusion, genital FDE is uncommon in children, but it is important to recognize this peculiar drug side effect. Though not serious or life threatening, it can be frightening to patients and parents. Simple discontinuation of the offending drug leads to prompt resolution of the eruption.
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